Literature DB >> 10102967

Mouse model of Helicobacter pylori infection: studies of gastric function and ulcer healing.

P C Konturek1, T Brzozowski, S J Konturek, J Stachura, E Karczewska, R Pajdo, P Ghiara, E G Hahn.   

Abstract

BACKGROUND: Helicobacter pylori infection in humans is a major risk factor for peptic ulcer, but studies on the relation between H. pylori infection and gastric pathology are limited due to a deficiency of convenient animal models resembling this infection in humans.
METHODS: We studied the effects of inoculation of conventional BALB/c mice with CagA and VacA positive (type I) H. pylori or CagA and VacA negative H. pylori (type II) strains on gastric secretion and healing of chronic acetic acid-induced ulcers in mouse stomachs. The ulcer area, gastric blood flow, plasma interleukin (IL)-1beta and IL-12, as well as plasma gastrin and gastric luminal somatostatin were determined. Gastric mucosal biopsy samples were also taken for assessment of the presence of viable H. pylori using a rapid urease test, H. pylori-culture and the RT-PCR analysis of the signal for H. pylori CagA.
RESULTS: Gastric acid and pepsin secretion was reduced by over 50% immediately after H. pylori inoculation and accompanied by a significant increment in plasma gastrin and fall in gastric luminal somatostatin content observed over all test days, particularly in mice infected with type I H. pylori. The area of ulcers in vehicle-treated controls decreased significantly starting from day 2 after ulcer induction and then continued to decline for a further 14 days to heal almost completely after 28 days. In contrast, the ulcers were present until day 28 in all mice infected with type I or type II H. pylori strains, being significantly larger, especially with type I H. pylori infection. The gastric blood flow at the ulcer margin and ulcer crater in vehicle-treated mice gradually increased with decreasing ulcer size, after 14 and 28 days reaching a value which was not significantly different from that in vehicle-administered mice. In contrast, the gastric blood flow in type I H. pylori and, to a lesser extent, in type II H. pylori infected mice was significantly lower than in vehicle controls, both at the margin and at the crater of ulcers at all tested days. Histological changes such as oedema or congestion of surface epithelium were found after 7 days whereas mucosal inflammatory infiltration appeared after 14 days with a further increase after 28 days, especially in type I H. pylori and to a lesser extent in type II H. pylori infected mice. Plasma IL-1beta and IL-12 were significantly elevated at all tested days of ulcer healing and their increments were significantly higher in type I than in type II H. pylori infection.
CONCLUSIONS: Conventional mice with gastric ulcers can be successfully infected by both toxigenic and nontoxigenic H. pylori strains, and this infection causes an immediate suppression of gastric secretion and markedly delays the healing of ulcers due to the fall in mucosal microcirculation in the ulcer region, cytokine release and an impairment in the gastrin-somatostatin link that appears to be independent of gastritis and more pronounced with infection of toxigenic than nontoxigenic strains.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10102967     DOI: 10.1046/j.1365-2036.1999.00476.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  13 in total

1.  Inhibition of carbachol stimulated acid secretion by interleukin 1beta in rabbit parietal cells requires protein kinase C.

Authors:  I L Beales; J Calam
Journal:  Gut       Date:  2001-06       Impact factor: 23.059

2.  Experimental infection of pigs with 'Candidatus Helicobacter suis'.

Authors:  A Hellemans; K Chiers; A Decostere; M De Bock; F Haesebrouck; R Ducatelle
Journal:  Vet Res Commun       Date:  2007-05       Impact factor: 2.459

3.  Interferon-γ inhibits ghrelin expression and secretion via a somatostatin-mediated mechanism.

Authors:  Jesper A B Strickertsson; Kristina B V Døssing; Anna J M Aabakke; Hans-Olof Nilsson; Thomas V O Hansen; Ulrich Knigge; Andreas Kjær; Torkel Wadström; Lennart Friis-Hansen
Journal:  World J Gastroenterol       Date:  2011-07-14       Impact factor: 5.742

4.  Development of an interleukin-12-deficient mouse model that is permissive for colonization by a motile KE26695 strain of Helicobacter pylori.

Authors:  Paul S Hoffman; Neeraj Vats; Donna Hutchison; Jared Butler; Kenneth Chisholm; Gary Sisson; Ausra Raudonikiene; Jean S Marshall; Sander J O Veldhuyzen van Zanten
Journal:  Infect Immun       Date:  2003-05       Impact factor: 3.441

5.  Influence of Helicobacter pylori infection on healing and relapse of acetic acid ulcers in Mongolian gerbils.

Authors:  Yoshihiro Keto; Misako Ebata; Kazuyoshi Tomita; Susumu Okabe
Journal:  Dig Dis Sci       Date:  2002-04       Impact factor: 3.199

6.  Toxigenic Helicobacter pylori induces changes in the gastric mucosal microcirculation in rats.

Authors:  N Kalia; K D Bardhan; J C Atherton; N J Brown
Journal:  Gut       Date:  2002-11       Impact factor: 23.059

7.  Treatment of Helicobacter gastritis with IL-4 requires somatostatin.

Authors:  Yana Zavros; Sivaprakash Rathinavelu; John Y Kao; Andrea Todisco; John Del Valle; Joel V Weinstock; Malcolm J Low; Juanita L Merchant
Journal:  Proc Natl Acad Sci U S A       Date:  2003-10-10       Impact factor: 11.205

8.  Helicobacter pylori prevents proliferative stage of angiogenesis in vitro: role of cytokines.

Authors:  Lesley Jenkinson; Karna Dev Bardhan; John Atherton; Neena Kalia
Journal:  Dig Dis Sci       Date:  2002-08       Impact factor: 3.199

9.  Modification in the ppk gene of Helicobacter pylori during single and multiple experimental murine infections.

Authors:  Sarah Ayraud; Blandine Janvier; Laurence Salaun; Jean-Louis Fauchère
Journal:  Infect Immun       Date:  2003-04       Impact factor: 3.441

10.  Motility and chemotaxis mediate the preferential colonization of gastric injury sites by Helicobacter pylori.

Authors:  Eitaro Aihara; Chet Closson; Andrea L Matthis; Michael A Schumacher; Amy C Engevik; Yana Zavros; Karen M Ottemann; Marshall H Montrose
Journal:  PLoS Pathog       Date:  2014-07-17       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.